Wealth Enhancement Advisory Services
CYTH

Wealth Enhancement Advisory Services’s Cyclo Therapeutics, Inc. Common Stock CYTH Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio CYTH Stock Details CYTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-18,285
Closed -$10.8K – 3201
2024
Q4 		$10.8K Sell
18,285
-5,115
-22% -$3.55K ﹤0.01% 2926
2024
Q3 		$18.5K Buy
23,400
+3,000
+15% +$3K ﹤0.01% 2672
2024
Q2 		$25.9K Hold
20,400
– – ﹤0.01% 2476
2024
Q1 		$28.4K Buy
20,400
+1,887
+10% +$3.12K ﹤0.01% 2372
2023
Q4 		$29.4K Buy
+18,513
New +$23.6K ﹤0.01% 2236

Wealth Enhancement Advisory Services's CYTH Position: Q1 2025 in Review

Wealth Enhancement Advisory Services sold out of Cyclo Therapeutics, Inc. Common Stock (CYTH) in Q1 2025, closing a stake of 18,285 shares — an estimated $10.8K sold.

Wealth Enhancement Advisory Services first reported a position in CYTH in Q4 2023 and held it in 5 quarters. The position peaked at $29.4K in Q4 2023. 0 funds tracked by Wall St. Rank hold CYTH as of Q1 2025.

  • Wealth Enhancement Advisory Services reported no remaining Cyclo Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Wealth Enhancement Advisory Services sold 18,285 Cyclo Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $10.8K.
  • Wealth Enhancement Advisory Services first reported a position in Cyclo Therapeutics, Inc. Common Stock in Q4 2023 and held it in 5 quarters.
  • Wealth Enhancement Advisory Services's Cyclo Therapeutics, Inc. Common Stock position peaked at $29.4K in Q4 2023.
  • 0 funds tracked by Wall St. Rank held Cyclo Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Wealth Enhancement Advisory Services's 13F filing for Q1 2025, filed 16 Apr 2025.